Skip to main content
In stock|Immunotherapy (Monoclonal Antibody)

Elotuzumab

Oncology TypeHematologic (Multiple Myeloma)
Drug Class / MechanismAnti-CD38 / SLAMF7 mAb
No Image
Description

Elotuzumab is classified as an Anti-CD38 / SLAMF7 mAb, sourced for use within our Immunotherapy (Monoclonal Antibody) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Monoclonal Antibody)
Oncology TypeHematologic (Multiple Myeloma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3